SINTX Technologies to Participate in Noble Capital Markets’ Emerging Growth Virtual Equity Conference on February 4–5
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
SINTX Technologies (NASDAQ: SINT) will present at the Noble Capital Markets Emerging Growth Virtual Equity Conference on February 4–5, 2026, with its presentation on Wednesday, February 4, 2026 at 12:00 p.m. ET.
The webcast will be available via the company’s investor site. Management will provide updates on operational progress, strategic priorities, its silicon nitride biomaterial platform, recent regulatory milestones, and opportunities in orthopedic, spine, and patient-specific applications.
Details
News Market Reaction – SINT
On Jan 29, the day this news came out, SINT closed 2.41% below the previous close. That session’s volume was 2.1x the stock’s average daily volume.
Data tracked by StockTitan Argus for the Jan 29 session.
Key Figures
- Registered shares
- 1,741,539 shares
- Resale registration on Form S-3
- Common warrant shares
- 1,649,147 shares
- Included in S-3 resale registration
- Placement agent warrant shares
- 92,392 shares
- Included in S-3 resale registration
- Potential proceeds
- $8.3 million
- If warrants in S-3 are exercised for cash
- Common warrant exercise price
- $4.79
- Warrants covered by S-3 resale registration
- Placement warrant price 1
- $4.3844
- Placement agent warrants in S-3
- Placement warrant price 2
- $4.3125
- Placement agent warrants in S-3
- Share price pre-news
- $3.32
- Prior close before Jan 29, 2026 conference announcement
Historical Context
-
Announcement of participation in Sidoti virtual investor conference with webcast access.
-
Supply deal with Evonik for SiN/PEEK compound for AI-assisted 3D-printed implants.
-
Q3 2025 update highlighting FDA clearance, first revenues, capital raised, and cost savings.
-
Launch of OsseoSculpt biologic complementing cleared SINAPTIC Foot & Ankle system.
-
FDA 510(k) clearance for SINAPTIC Foot & Ankle Osteotomy Wedge System enabling U.S. entry.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
silicon nitride medical
biomaterial medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
SALT LAKE CITY, Utah, Jan. 29, 2026 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”), an advanced ceramics and biomaterials company focused on silicon-nitride-based medical technologies, today announced that its management team will present at the Noble Capital Markets Emerging Growth Virtual Equity Conference, to be held February 4–5, 2026.
The Company’s participation comes at an important stage in its evolution, following a period of operational restructuring, enhanced financial discipline, and a renewed strategic focus on its core medical-technology platforms. With a more streamlined cost structure, greater visibility into its balance-sheet, and several strategic initiatives underway, SINTX believes the Noble Conference provides a constructive forum to engage with institutional investors seeking differentiated medtech opportunities.
Noble Capital Markets’ Emerging Growth Virtual Equity Conference
- Dates: February 4–5, 2026
- Presentation Date & Time: Wednesday, February 4, 2026, at 12:00 p.m. ET
- Webcast: https://investors.sintx.com/news-events/events-presentations
During the conference, SINTX management will provide an update on the Company’s operational progress and strategic priorities, including its expanding silicon nitride biomaterial platform, recent regulatory milestones, and opportunities for value creation in orthopedic, spine, and patient-specific applications.
Noble’s Emerging Growth Conference is widely followed by institutional investors, family offices, and research analysts focused on fundamentally driven, under-followed growth companies, and SINTX looks forward to participating in one-on-one meetings and investor discussions throughout the event.
To schedule a one-on-one meeting with SINTX Technologies’ management team, please contact KCSA Strategic Communications at Sintx@kcsa.com.
To be added to the SINTX Technologies email distribution list, please email Sintx@kcsa.com with “SINT” in the subject line.
About SINTX Technologies, Inc.
Based in Salt Lake City, Utah, SINTX Technologies, Inc. (NASDAQ: SINT) is a pioneer in advanced ceramics specializing in silicon nitride-based materials for medical and other high-value applications. SINTX’s biomaterials have been implanted in humans since 2008, and the company continues to expand its portfolio of next-generation orthopedic, spine, and patient-specific solutions through strategic innovation and partnerships.
This press release contains forward-looking statements within the meaning of the federal securities laws that involve risks and uncertainties, and actual results may differ materially from those described.
SINTX Contacts:
Jack Perkins or Maria Hocut
KCSA Strategic Communications
Sintx@kcsa.com
SINTX Technologies, Inc.
801.839.3502
IR@sintx.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.